StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report issued on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Trading Up 4.4 % Shares of NASDAQ AKTX opened at $1.89 on Friday. Akari Therapeutics has a 1 year low of $1.66 and a […]